Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 May 11;7:1787. doi: 10.1038/s41598-017-01973-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Ruxolitinib reduces disease severity in a murine model of chronic pancreatitis. (a) Treatment schedule for in vivo experiments. Mice were administered caerulein or PBS (control) via intraperitoneal injection 6X/day, 3 days/week, for 5 weeks. Ruxolitinib was given 2X/day via oral gavage during the final week. (b) IHC analysis of pSTAT3 from healthy control mice, pancreatitis-induced mice, and pancreatitis-induced mice treated with ruxolitinib or vehicle control. (c) Serum lipase and amylase levels were analyzed upon euthanasia (* indicates p < 0.05). (d) FFPE pancreata from caerulein-injected mice treated with either ruxolitinib or vehicle were stained for H&E, Masson’s Trichrome, CD3, and α-SMA. Images are representative of 5 mice per group. Slides were quantified using Vectra automated quantitative pathology imaging system and InForm analysis. Graphs display percent acini, fibrosis, CD3, and α-SMA (* indicates p < 0.05).